ND0612, a novel liquid formulation of levodopa/carbidopa for subcutaneous infusion in patients with Parkinson's disease achieves stable levodopa plasma levels when administered in low and high doses

被引：0

作者：

Giladi, Nir ^{[1
]}

Caraco, Yoseph ^{[2
]}

Gurevich, Tanya ^{[3
]}

Djaldetti, Ruth ^{[4
]}

Adar, Liat ^{[5
]}

Cohen, Yael ^{[5
]}

Minei, Tamar Rachmilewitz ^{[5
]}

Oren, Sheila ^{[5
]}

机构：

[1] Tel Aviv Med Ctr & Sch Med, Tel Aviv, Israel

[2] Hadassah Med Ctr, Jerusalem, Israel

[3] Sackler Sch Med, Tel Aviv, Israel

[4] Tel Aviv Univ, Petah Tiqwa, Israel

[5] NeuroDerm Ltd, Rehovot, Israel

来源：

NEUROLOGY | 2017年 / 88卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

S4.002

引用

页数：3

共 39 条

[31] iNDiGO: A Multicenter, Randomized, Double-blind, Placebo-controlled, Study of Continuous ND0612 Infusion with Adjunct Oral Levodopa in Fluctuating Parkinson's Disease
LeWitt, Peter
Stocchi, Fabrizio
Isaacson, Stuart
Leionen, Mika
Rachmilewitz, Tami
Case, Ryan
Kieburtz, Karl
Olanow, C. Warren
MOVEMENT DISORDERS, 2018, 33 : S94 - S94
[32] Neuropsychological performance in stable and fluctuating Parkinson's disease patients at three different levodopa plasma levels
Kulisevsky, J
Avila, A
Barbanoj, M
Antonijoan, R
Berthier, ML
NEUROLOGY, 1996, 46 (02) : 1098 - 1098
[33] Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial (vol 43, pg 465, 2024)
Espay, A. J.
Stocchi, F.
Pahwa, R.
LANCET NEUROLOGY, 2024, 23 (06): : E10 - E10
[34] Comparison of IPX066, a Novel Extended-Release Oral Carbidopa-Levodopa Formulation, to Immediate-Release Carbidopa-Levodopa in Patients with Advanced Parkinson's Disease (PD)
Hsu, Ann
Metman, Leonard Verhagen
Ellenbogen, Aaron
O'Connell, Martin
Modi, Nishit B.
Kell, Sherron
Gupta, Suneel
NEUROLOGY, 2010, 74 (09) : A350 - A350
[35] Bilayer formulation of carbidopa/levodopa (IPX054) 50/200 mg given twice daily is comparable to standard carbidopa/levodopa 25/100 mg given four times daily in stable Parkinson's disease (PD) patients
Hinson, Vanessa
Goetz, Christopher
Leurgans, Sue
Fan, Wenqing
Hsu, Anne
NEUROLOGY, 2008, 70 (11) : A424 - A424
[36] Potential Psychosis Induced by a Sustained High Plasma Levodopa Concentration Due to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient With Parkinson's Disease: A Case Report
Tezuka, Toshiki
Nukariya, Tomonori
Kizuka, Yuta
Okusa, Shohei
Okochi, Ryotaro
Sakai, Yuto
Nihei, Yoshihiro
Nakahara, Jin
Seki, Morinobu
JOURNAL OF MOVEMENT DISORDERS, 2024, 17 (04) : 453 - 455
[37] Levodopa in combination with carbidopa does not affect plasma arginine vasopressin levels in treatment-naive older patients with Parkinson's disease: A before-after study
Arai, Motomi
NEUROENDOCRINOLOGY LETTERS, 2012, 33 (01) : 34 - 36
[38] The Impact of Long-Term Continuous Subcutaneous Apomorphine Infusion on the Reduction of Remaining Medications in Levodopa Equivalent Dosage and on Increasing Plasma Vitamin B12 Levels in Patients with Advanced Parkinson's disease (PD)
Phokaewvarangkul, O.
Bhidayasiri, R.
MOVEMENT DISORDERS, 2024, 39 : S397 - S398
[39] Open-label comparison of IPX066, a novel investigational carbidopa-levodopa (CD-LD) extended-release formulation, and controlled-release CD-LD (CR) in Parkinson's disease patients with motor fluctuation
Tetrud, J.
Liang, G.
Nausieda, P.
Hsu, A.
O'Connell, M.
Khanna, S.
Kell, S.
Ellenbogen, A.
Tanner, C. M.
Gupta, S.
MOVEMENT DISORDERS, 2014, 29 : S269 - S270

← 1 2 3 4 →